A phase II study of S-1 in combination with sorafenib in metastatic renal cell carcinoma.
Hideki Sakai
No relevant relationships to disclose
Kojiro Ohba
No relevant relationships to disclose
Katsuyoshi Hashine
No relevant relationships to disclose
Yoshihiko Tomita
No relevant relationships to disclose
Nobuo Shinohara
No relevant relationships to disclose
Masato Fujisawa
No relevant relationships to disclose
Masatoshi Eto
No relevant relationships to disclose
Seiichiro Ozono
No relevant relationships to disclose
Taiji Tsukamoto
Consultant or Advisory Role - Taiho Pharmaceutical Co., Ltd.
Hideyuki Akaza
Consultant or Advisory Role - Taiho Pharmaceutical
Seiji Naito
Consultant or Advisory Role - Ono Pharmaceutical ; Pfizer